#molnupiravir

FDA's emergency use approval of COVID pill molnupiravir a 'big step' in PH's fight vs pandemic---Faberco

Ayala brings anti-COVID drug Molnupiravir to PH

Molnupiravir now available in Manila's 6 district hospitals, COVID-19 Field Hospital

Good news! Molnupiravir now available to patients under OVP’s teleconsult service

First batch of anti-COVID drug Molnupiravir to arrive in PH on Nov. 18

Pharma exec says anti-COVID pill Molnupiravir works against variants, reduces hospitalization

Experimental oral coronavirus disease (COVID-19) antiviral drug, Molnupiravir, is said to be effective against known variants of the virus, including the highly transmissible Delta variant, and reduce the risk of hospitalization for patients.

Molnupiravir won’t cost $700 in PH; to be accessible to public----pharma exec

Budget bill amendment sought for procurement of game-changing COVID-19 pills

DOH closely monitoring developments on Molnupiravir trials

Hospitals call for more volunteers in Molnupiravir clinical trials vs COVID-19

Bongbong, Sara back local production of Molnupiravir

COVID anti-viral drug Molnupiravir access, supply being set up for MSMEs

Faberco assures access to COVID-19 drug Molnupiravir

Taguig LGU distributes oral COVID-19 drug molnupiravir amid surge in cases

FDA warns against unauthorized sale of molnupiravir

The Food and Drug Administration (FDA) on Sunday, Jan. 16, warned all healthcare professionals and the public against buying molnupiravir, an investigational drug used in the treatment of coronavirus disease (COVID-19), from unauthorized entities.

DOH issues advisory amid reports of fake Molnupiravir

Local firm's Molnupiravir may cost P50 to P75 per capsule - FDA

Clinical trial seeks to test Molnupiravir's potential in preventing COVID-19

A clinical trial is seeking to test Molnupiravir's potential as post-exposure treatment in preventing coronavirus disease (COVID-19), an infectious disease expert said Saturday, Feb. 5.

COVID-19 medications are essential in exiting pandemic – expert

WHO OKs molnupiravir for Covid-19 patients at 'risk of hospitalization'